Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders

Heart

Volumn 103, Issue 23, 2017, Pages 1867-1873

  Dregan, Alex ^a,b   Chowienczyk, Phil ^a   Molokhia, Mariam ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiac risk factors and prevention; Coronary artery disease; Diabetes; Stroke; Systemic inflammatory diseases

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ALL CAUSE MORTALITY; ANKYLOSING SPONDYLITIS; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; COHORT ANALYSIS; COMPARATIVE STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; MORBIDITY; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; TREATMENT DURATION; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM; ADOLESCENT; AGED; BIOBANK; CAUSE OF DEATH; CHRONIC DISEASE; INFLAMMATION; MORTALITY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL SPECIMEN BANKS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED KINGDOM; YOUNG ADULT;

EID: 85035063519     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2017-311214     Document Type: Article

References (30)

1. Dregan A, Charlton J, Chowienczyk P, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014;130:837-44.
2. Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J 2015;36:482-9.
3. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011;70:929-34.
4. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
5. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-6.
6. G elfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
7. G rainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010;375:657-63.
8. Bewtra M, Kaiser LM, TenHave T, et al. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013;19:599-613.
9. H arold JG, Williams KA. President's page: Disparities in cardiovascular care: finding ways to narrow the gap. J Am Coll Cardiol 2013;62:563-5.
10. N g MK, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. Heart 2004;90:829-30.
11. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779.
12. Stern MP. Diabetes and cardiovascular disease. The 'common soil' hypothesis. Diabetes 1995;44:369-74.
13. Lu J, Mu Y, Su Q, et al. Reduced Kidney Function Is Associated With Cardiometabolic Risk Factors, Prevalent and Predicted Risk of Cardiovascular Disease in Chinese Adults: Results From the REACTION Study. J Am Heart Assoc 2016;5.
14. Stefan N, Häring HU, Hu FB, et al. Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications. Lancet Diabetes Endocrinol 2016;4:457-67.
15. Tyrrell J, Jones SE, Beaumont R, et al. Height, body mass index, and socioeconomic status: mendelian randomisation study in UK Biobank. BMJ 2016;352:i582.
16. G reenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004;160:301-5.
17. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002;2:8.
18. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
19. Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002;61:567-9.
20. Singh S, Kullo IJ, Pardi DS, et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol 2015;12:26-35.
21. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015;74:326-32.
22. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish realworld cohort study. J Intern Med 2013;273:197-204.
23. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and metaanalysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011;108:1362-70.
24. Osterman MT, Yang YX, Brensinger C, et al. No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol 2011;9:875-80.
25. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol 2012;8:214-23.
26. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7.
27. Agca R, Heslinga SC, van Halm VP, et al. Atherosclerotic cardiovascular disease in patients with chronic inflammatory joint disorders. Heart 2016;102:790-5.
28. N tuk UE, Gill JM, Mackay DF, et al. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care 2014;37:2500-7.
29. Barra LJ, Pope JE, Hitchon C, et al. The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Rheumatology 2017:kew474.
30. Emanuel G, Charlton J, Ashworth M, et al. Cardiovascular risk assessment and treatment in chronic inflammatory disorders in primary care. Heart 2016;102:1957-62.